Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:DiVA.org:uu-98175" > Heparan sulfate and...

1 of 1
Previous record
Next record
To hitlist

Details
MARC

Bode, Lars (author)

Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function

Article/chapterEnglish2008

Publisher, publication year, extent ...

2008
printrdacarrier

Numbers

LIBRIS-ID:oai:DiVA.org:uu-98175
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-98175URI
https://doi.org/10.1172/JCI32335DOI

Supplementary language notes

Language:English
Summary in:English

Part of subdatabase

SwePubSwePub

Classification

Subject category:ref swepub-contenttype
Subject category:art swepub-publicationtype

Notes

Patients with protein-losing enteropathy (PLE) fail to maintain intestinal epithelial barrier function and develop an excessive and potentially fatal efflux of plasma proteins. PLE occurs in ostensibly unrelated diseases, but emerging commonalities in clinical observations recently led us to identify key players in PLE pathogenesis. These include elevated IFN-gamma, TNF-alpha, venous hypertension, and the specific loss of heparan sulfate proteoglycans from the basolateral surface of intestinal epithelial cells during PLE episodes. Here we show that heparan sulfate and syndecan-1, the predominant intestinal epithelial heparan sulfate proteoglycan, are essential in maintaining intestinal epithelial barrier function. Heparan sulfate- or syndecan-1-deficient mice and mice with intestinal-specific loss of heparan sulfate had increased basal protein leakage and were far more susceptible to protein loss induced by combinations of IFN-gamma, TNF-alpha, and increased venous pressure. Similarly, knockdown of syndecan-1 in human epithelial cells resulted in increased basal and cytokine-induced protein leakage. Clinical application of heparin has been known to alleviate PLE in some patients but its unknown mechanism and severe side effects due to its anticoagulant activity limit its usefulness. We demonstrate here that non-anticoagulant 2,3-de-O-sulfated heparin could prevent intestinal protein leakage in syndecan-deficient mice, suggesting that this may be a safe and effective therapy for PLE patients.

Subject headings and genre

MEDICINE
MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

Salvestrini, Camilla (author)
Park, Pyong Woo (author)
Li, Jin-PingUppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi(Swepub:uu)jinpili (author)
Esko, Jeffrey D (author)
Yamaguchi, Yu (author)
Murch, Simon (author)
Freeze, Hudson H (author)
Uppsala universitetInstitutionen för medicinsk biokemi och mikrobiologi (creator_code:org_t)

Related titles

In:Journal of Clinical Investigation118:1, s. 229-2380021-97381558-8238

Internet link

Find in a library

Journal of Clinical Investigation (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Bode, Lars; Salvestrini, Cam ...; Park, Pyong Woo; Li, Jin-Ping; Esko, Jeffrey D; Yamaguchi, Yu; show more...; Murch, Simon; Freeze, Hudson H; show less...

Articles in the publication: Journal of Clini ...

By the university: Uppsala University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se